Table 1.
General Characteristics
| Variable | Patients |
|---|---|
| General characteristics | |
| No. of patients | 118 |
| Age, y | 49 ± 17 |
| Sex, female, No. (%) | 81 (69) |
| BMI | 26 ± 4.9 |
| Follow-up time, y | 5.5 (3-8) |
| NYHA class (n = 106), No. (%) | |
| I | 8 (7) |
| II | 40 (35) |
| III | 58 (51) |
| IV | 7 (6) |
| Treatments during follow-up | |
| Monotherapy, No. (%) | 52 (44) |
| Duotherapy, No. (%) | 60 (51) |
| Triple therapy, No. (%) | 6 (5) |
| Calcium antagonists, No. (%) | 10 (8) |
| Endothelin antagonists, No. (%) | 84 (71) |
| PDE5 inhibitors, No. (%) | 76 (64) |
| Prostacyclin analog, No. (%) | 18 (15) |
| Events | |
| No event > 5 y, No. (%) | 42 (36) |
| No event < 5 y, No. (%) | 32 (27) |
| Event > 5 y, No. (%) | 20 (17) |
| Event < 5 y, No. (%) | 24 (20) |
Data presented as mean ± SD or median (interquartile range) when data are not normally distributed. NYHA = New York Heart Association; PDE5 = phosphodiesterase 5.